Merck CEO Frazier says pharma is in the political 'crosshairs' by Eric Sagonowsky Thursday, October 10, 2019 Merck CEO Ken Frazier knows the industry is in the political "crosshairs," but he cautioned against policies that could "hurt innovation."
Big Pharma CEOs' Chinese names: What they mean by Angus Liu Tuesday, October 1, 2019 Big Pharma CEOs have their own way of cozying up to the world’s second largest pharmaceutical market—by getting themselves Chinese names.
Is there life beyond Keytruda? Merck makes its case by Arlene Weintraub Thursday, June 20, 2019 Merck CEO Ken Frazier and his colleagues vowed during the company's Investor Day that a healthy pipeline will drive margin expansion.
Merck scouts replacements for CEO Frazier: report by Eric Sagonowsky Wednesday, June 19, 2019 Merck is scouting replacements for CEO Ken Frazier with a preference toward an internal candidate, Bloomberg reports.
Investors aim to spotlight ties between pricing, exec pay by Eric Sagonowsky Tuesday, April 23, 2019 With resolutions on the ballot at six top U.S. drugmakers, investors aim to learn how drug pricing affects executive pay.
Loyalty pays: Merck CEO Ken Frazier scores 19% raise by Arlene Weintraub Wednesday, April 10, 2019 Ken Frazier’s total compensation for 2018 was $20.9 million, up from $17.6 million in 2017, enough to put him among the industry's highest paid.
Merck CEO follows father's advice to 'tune out' critics by Arlene Weintraub Tuesday, March 26, 2019 Merck CEO Kenneth Frazier remains unflustered by his company's challenges, thanks to advice his father gave him when he was a teenager in Philadelphia.
5. Merck & Co. by Carly Helfand It’s not hard to see how Merck grew its revenues in 2018, what with Keytruda’s sales swelling by billions. But the PD-1 superstar wasn’t in it alone.
Pharma CEOs in Washington: The latest from the Senate pricing hearing by Eric Sagonowsky Tuesday, February 26, 2019 Once the Senate finance committee’s drug pricing hearing started on Tuesday, it didn’t take long for sparks to fly.
